Hair Repigmentation During Immunotherapy Treatment With an Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Agent for Lung Cancer | Zendy

Noelia Rivera | Zendy; Aram Boada | Zendy; María Isabel Bielsa | Zendy; María Teresa FernándezFigueras | Zendy; Enric Carcereny | Zendy; María Teresa Cabero Morán | Zendy; Carlos Ferrándiz | Zendy

Open Access

Hair Repigmentation During Immunotherapy Treatment With an Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Agent for Lung Cancer

Author(s) -

Noelia Rivera,

Aram Boada,

María Isabel Bielsa,

María Teresa FernándezFigueras,

Enric Carcereny,

María Teresa Cabero Morán,

Carlos Ferrándiz

Publication year - 2017

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2017.2106

Subject(s) - medicine , lung cancer , adverse effect , nivolumab , cancer , dermatology , skin cancer , immunotherapy , oncology

New targeted therapies for cancer have been released in recent years, opening new horizons in the treatment of patients with cancer. However, their related adverse events (AE) are not fully characterized. Hair repigmentation (HR) is a nondescribed effect secondary to anti-programmed cell death 1 (anti-PD-1) and anti-programmed cell death ligand 1 (anti-PD-L1 ) therapy for treatment of lung cancer (LC), in opposition to the vitiligo reactions that develop during melanoma treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research